Metoclopramide NDC 62559-295

NDC codes

FDA NDC Directory

Product NDC (as listed)62559-295Labeler and product segments. Claims need a package NDC.

Product NDC at billing width62559-0295Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
62559-295-01	62559029501	100 TABLET in 1 BOTTLE, PLASTIC (62559-295-01)Marketed from Dec 13, 2021

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Metoclopramide
Generic name (nonproprietary): metoclopramide
Active ingredients: Metoclopramide hydrochloride — 5 mg/1
Dosage form: Tablet
Route: Oral
Labeler: ANI Pharmaceuticals, Inc.
Product type: Prescription drug
Marketing category: NDA authorized genericApplication NDA 017854
Marketing start: Dec 13, 2021
Marketing end: May 31, 2027
Other FDA classes: Dopamine D2 Antagonists (Mechanism)
Identifiers: Product ID 62559-295_6d4ed2af-6756-4e7a-8325-820490408f5fSPL ID 6d4ed2af-6756-4e7a-8325-820490408f5fSPL set ID 797aad80-0597-42f8-99d5-39de180c3b5aRxCUI 311666, 311668UNII W1792A2RVDUPC 0362559295017, 0362559296014
Pharmacologic class: Dopamine-2 Receptor Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N462559029501 followed by a unit qualifier and the quantity

Package 62559-0295-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 18, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Metoclopramide Tablets USP are indicated for the: • Treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy. • Relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Limitations of Use : • Metoclopramide Tablets USP have not been shown to be safe and effective for the treatment of symptomatic, documented gastroesophageal reflux for longer than 12 weeks [see Warnings and Precautions ( 5.1 )] . • Metoclopramide Tablets USP are not recommended for use in pediatric patients due to the risk of developing tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobine…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 017854

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 017854
Product	Strength	Form · route	Labeler	Product NDC
Reglanmetoclopramide hydrochloride	Metoclopramide hydrochloride 10 mg/1	TabletOral	ANI Pharmaceuticals, Inc.	62559-166
Reglanmetoclopramide hydrochloride	Metoclopramide hydrochloride 5 mg/1	TabletOral	ANI Pharmaceuticals, Inc.	62559-165
Metoclopramide	Metoclopramide hydrochloride 10 mg/1	TabletOral	ANI Pharmaceuticals, Inc.	62559-296
Metoclopramide	Metoclopramide hydrochloride 10 mg/1	TabletOral	REMEDYREPACK INC.	70518-4541
Metoclopramide	Metoclopramide hydrochloride 5 mg/1	TabletOral	Redpharm Drug	67296-2213